ป้ายกำกับ: study

Mitsubishi Shipbuilding and INPEX Complete Conceptual Study for Ammonia Bunkering Vessel

By: Hansa

On: กุมภาพันธ์ 2, 2023

In: JCN Newswire

TOKYO, Feb 2, 2023 – (JCอ่านต่อไป

Lecanemab Receives Priority Review Status in Japan

By: Hansa

On: มกราคม 30, 2023

In: JCN Newswire

TOKYO and CAMBRIDGE, Mass., Jaอ่านต่อไป

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan

By: Hansa

On: มกราคม 16, 2023

In: JCN Newswire

TOKYO and CAMBRIDGE, Mass., Jaอ่านต่อไป

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe

By: Hansa

On: มกราคม 11, 2023

In: JCN Newswire

TOKYO, Jan 11, 2023 – (Jอ่านต่อไป

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

By: Chatri

On: มกราคม 5, 2023

In: ACN Newswire

ROCKVILLE, MD and SHENZHEN, CHอ่านต่อไป

MHI Signs MoU with Chile’s Guacolda Energia for Feasibility Study of Ammonia Co-Firing at a Coal-Fired Thermal Power Plant

By: Hansa

On: ธันวาคม 7, 2022

In: JCN Newswire

TOKYO, Dec 7, 2022 – (JCอ่านต่อไป

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

By: Hansa

On: พฤศจิกายน 30, 2022

In: JCN Newswire

TOKYO, Nov 30, 2022 – (Jอ่านต่อไป

Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease in the New England Journal of Medicine

By: Hansa

On: พฤศจิกายน 30, 2022

In: JCN Newswire

TOKYO, Nov 30, 2022 – (Jอ่านต่อไป

AJG Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

By: Chatri

On: พฤศจิกายน 17, 2022

In: ACN Newswire

ROCKVILLE, MD and SHENZHEN, CHอ่านต่อไป

American Journal of Gastroenterology Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

By: Chatri

On: พฤศจิกายน 17, 2022

In: ACN Newswire

ROCKVILLE, MD and SHENZHEN, CHอ่านต่อไป

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon

By: Hansa

On: พฤศจิกายน 2, 2022

In: JCN Newswire

TOKYO, Nov 2, 2022 – (JCอ่านต่อไป

Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination

By: Hansa

On: พฤศจิกายน 2, 2022

In: JCN Newswire

TOKYO, Nov 2, 2022 – (JCอ่านต่อไป

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA

By: Chatri

On: สิงหาคม 24, 2022

In: ACN Newswire

HONG KONG, Aug 24, 2022 &#8211อ่านต่อไป

Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022

By: Hansa

On: กรกฎาคม 26, 2022

In: JCN Newswire

TOKYO, Jul 26, 2022 – (Jอ่านต่อไป

TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally

By: Chatri

On: กรกฎาคม 20, 2022

In: ACN Newswire

ADELAIDE, AUS, Jul 20, 2022 &#อ่านต่อไป

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

By: Chatri

On: พฤษภาคม 13, 2022

In: ACN Newswire

SHANGHAI, CHINA, May 13, 2022 อ่านต่อไป

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

By: Hansa

On: พฤษภาคม 10, 2022

In: JCN Newswire

TOKYO and CAMBRIDGE, Mass., Maอ่านต่อไป

Joint Feasibility Study on the Commercialization of Sustainable Aviation Fuel

By: Hansa

On: เมษายน 19, 2022

In: JCN Newswire

TOKYO, Apr 19, 2022 – (Jอ่านต่อไป

Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting

By: Hansa

On: มีนาคม 22, 2022

In: JCN Newswire

CAMBRIDGE, Mass., and TOKYO, Mอ่านต่อไป

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

By: Hansa

On: มีนาคม 4, 2022

In: JCN Newswire

TOKYO, Mar 4, 2022 – (JCอ่านต่อไป

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

By: Chatri

On: กุมภาพันธ์ 7, 2022

In: ACN Newswire

HONG KONG, Feb 7, 2022 –อ่านต่อไป

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

By: Hansa

On: มกราคม 19, 2022

In: JCN Newswire

TOKYO, Jan 19, 2022 – (Jอ่านต่อไป

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

By: Hansa

On: มกราคม 17, 2022

In: JCN Newswire

TOKYO, Jan 17, 2022 – (Jอ่านต่อไป

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

By: Hansa

On: ธันวาคม 24, 2021

In: JCN Newswire

TOKYO, Dec 24, 2021 – (Jอ่านต่อไป